Publication | Open Access
Comparison of Simoa<sup>TM</sup> and Ella<sup>TM</sup> to assess serum neurofilament‐light chain in multiple sclerosis
78
Citations
8
References
2021
Year
We compared Simoa<sup>TM</sup> and Ella<sup>TM</sup> immunoassays to assess serum neurofilament-light chain levels in 203 multiple sclerosis patients from the OFSEP HD study. There was a strong correlation (ρ = 0.86, p < 0.0001) between both platforms. The Ella<sup>TM</sup> instrument overestimated values by 17%, but as the data were linear (p = 0.57), it was possible to apply a correction factor to Ella<sup>TM</sup> results. As for Simoa<sup>TM</sup> , serum neurofilament-light chain levels measured by Ella<sup>TM</sup> were correlated with age and EDSS and were significantly higher in active multiple sclerosis, suggesting that these assays are equivalent and can be used in routine clinical practice.
| Year | Citations | |
|---|---|---|
Page 1
Page 1